Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Simpson AG, Stevens JR, Lukes J. The evolution and diversity of kinetoplastid flagellates. Trends Parasitol.22(4),168–174 (2006).Crossref, Medline, CAS, Google Scholar
• 2  The WHO. Education is key to controlling visceral leishmaniasis. Bull. World Health Organ.88(1),11–12 (2010).Crossref, Medline, Google Scholar
• 3  BenSaid M, Guerbouj S, Saghrouni F, Fathallah-Mili A, Guizani I. Occurrence of Leishmania infantum cutaneous leishmaniasis in central Tunisia. Trans. R. Soc. Trop. Med. Hyg.100(6),521–526 (2006).Crossref, Medline, CAS, Google Scholar
• 4  Lukes J, Mauricio IL, Schonian G. et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl Acad. Sci. USA104(22),9375–9380 (2007).Crossref, Medline, CAS, Google Scholar
• 5  Dujardin JC, Campino L, Canavate C et al. Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg. Infect. Dis.14(7),1013–1018 (2008).Crossref, Medline, Google Scholar
• 6  Christodoulou V, Antoniou M, Ntais P et al. Re-emergence of visceral and cutaneous leishmaniasis in the Greek Island of Crete. Vector Borne Zoonotic Dis.12(3),214–222 (2012).Crossref, Medline, Google Scholar
• 7  Fischer D, Moeller P, Thomas SM, Naucke TJ, Beierkuhnlein C. Combining climatic projections and dispersal ability: a method for estimating the responses of sandfly vector species to climate change. PLoS Negl. Trop. Dis.5(11),e1407 (2011).Crossref, Medline, Google Scholar
• 8  Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg.95,239–243 (2001).Crossref, Medline, CAS, Google Scholar
• 9  Fyfe PK, Westrop GD, Silva AM, Coombs GH, Hunter WN. Leishmania TDR1 structure, a unique trimeric glutathione transferase capable of deglutathionylation and antimonial prodrug activation. Proc. Natl Acad. Sci. USA109(29),11693–11698 (2012).▪ Demonstration that pentavalent antimonials are activated in vivo by TDR1.Crossref, Medline, CAS, Google Scholar
• 10  Lira R, Sundar S, Makharia A et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis.180(2),564–567 (1999).Crossref, Medline, CAS, Google Scholar
• 11  Hadighi R, Mohebali M, Boucher P et al. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med.3(5),e162 (2006).Crossref, Medline, Google Scholar
• 12  Sundar S, Pai K, Kumar R et al. Resistance to treatment in Kala-azar: speciation of isolates from northeast India. Am. J. Trop. Med. Hyg.65(3),193–196 (2001).Crossref, Medline, CAS, Google Scholar
• 13  Abdo MG, Elamin WM, Khalil EA, Mukhtar MM. Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation. East Mediterr. Health J.9(4),837–843 (2003).Crossref, Medline, CAS, Google Scholar
• 14  Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des.8,319–342 (2002).Crossref, Medline, CAS, Google Scholar
• 15  Shakya N, Bajpai P, Gupta S. Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs. J. Parasit. Dis.35(2),104–112 (2011).Crossref, Medline, Google Scholar
• 16  Davidson RN, Croft SL, Scott A et al.Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet337(8749),1061–1062 (1991).Crossref, Medline, CAS, Google Scholar
• 17  Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin. Microbiol. Rev.19(1),111–126 (2006).Crossref, Medline, CAS, Google Scholar
• 18  El-Sayed NM, Myler PJ, Blandin G et al. Comparative genomics oftrypanosomatid parasitic protozoa. Science309(5733),404–409 (2005).Crossref, Medline, CAS, Google Scholar
• 19  Colotti G, Ilari A. Polyamine metabolism in Leishmania: from arginine to trypanothione. Amino Acids40(2),269–285 (2011).▪ Informative review on the whole polyamine and trypanothione metabolism in Leishmania.Crossref, Medline, CAS, Google Scholar
• 20  Krauth-Siegel RL, Comini MA. Redox control in trypanosomatids parasitic protozoa with trypanothione-based thiol metabolism. Biochim. Biophys. Acta1780(11),1236–1248 (2008).Crossref, Medline, CAS, Google Scholar
• 21  Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A. Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science227(4693),1485–1487 (1985).Crossref, Medline, CAS, Google Scholar
• 22  Freason JA, Wyatt PG, Gilbert IH, Fairlamb AH. Target assessment for antiparasitic drug discovery. Trends Parasitol.23,589–595 (2007).Crossref, Medline, Google Scholar
• 23  Dumas C, Ouellette M, Tovar J et al. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J.16(10),2590–2598 (1997).Crossref, Medline, CAS, Google Scholar
• 24  Romao S, Castro H, Sousa C, Carvalho S, Tomas AM. The cytosolic tryparedoxin of Leishmania infantum is essential for parasite survival. Int. J. Parasitol.39,703–711 (2009).Crossref, Medline, CAS, Google Scholar
• 25  Barr SD, Gedamu L. Role of peroxidoxins in Leishmania chagasi survival. Evidence of an enzymatic defense against nitrosative stress. J. Biol. Chem.278,10816–10823 (2003).Crossref, Medline, CAS, Google Scholar
• 26  Comini MA, Krauth-Siegel RL, Flohe L. Depletion of the thioredoxin homologue tryparedoxin impairs antioxidative defence in African trypanosomes. Biochem. J.402,43–49 (2007).Crossref, Medline, CAS, Google Scholar
• 27  Wilkinson SR, Kelly JM. The role of glutathione peroxidases in trypanosomatids. Biol. Chem.384,517–525 (2003).Crossref, Medline, CAS, Google Scholar
• 28  Flohè L. The trypanothione system and the opportunities it offers to create drugs for the neglected kinetoplast diseases. Biotechnol. Adv.30,294–301 (2011).Crossref, Medline, Google Scholar
• 29  Eberle C, Burkhard JA, Stump B et al. Synthesis, inhibition potency, binding mode, and antiprotozoal activities of fluorescent inhibitors of trypanothione reductase based on mepacrine-conjugated diaryl sulfide scaffolds. ChemMedChem4,2034–2044 (2009).Crossref, Medline, CAS, Google Scholar
• 30  Eberle C, Lauber BS, Fankhauser D et al. Improved inhibitors of trypanothione reductase by combination of motifs: synthesis, inhibitory potency, binding mode, and antiprotozoal activities. ChemMedChem6,292–301 (2011).Crossref, Medline, CAS, Google Scholar
• 31  Meiering S, Inhoff O, Mies J et al. Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis. J. Med. Chem.48,4793–4802 (2005).Crossref, Medline, CAS, Google Scholar
• 32  Spinks D, Shanks EJ, Cleghorn LA et al. Investigation of trypanothione reductase as a drug target in Trypanosoma brucei. ChemMedChem4,2060–2069 (2009).Crossref, Medline, CAS, Google Scholar
• 33  Krieger S, Schwarz W, Ariyanayagam MR, Fairlamb AH, Krauth-Siegel RL, Clayton C. Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol. Microbiol.35(3),542–552 (2000).Crossref, Medline, CAS, Google Scholar
• 34  Wyllie S, Oza SL, Patterson S et al. Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods. Mol. Microbiol.74(3),529–540 (2009).Crossref, Medline, CAS, Google Scholar
• 35  Baiocco P, Poce G, Alfonso S et al. Inhibition of leishmania infantum trypanothione reductase by azole-based compounds: a comparative analysis with its physiological substrate by x-ray crystallography. ChemMedChem8,1175–1183 (2013).Crossref, Medline, CAS, Google Scholar
• 36  Fyfe PK, Oza SL, Fairlamb AH, Hunter WN. Leishmania trypanothione synthetase-amidase structure reveals a basis for regulation of conflicting synthetic and hydrolytic activities. J. Biol. Chem.283(25),17672–17680 (2008).▪▪ The crystal structure of trypanothione synthetase-amidase helps postulate the trypanothione synthesis mechanism together with the computational analysis of Koch et al.[40]Crossref, Medline, CAS, Google Scholar
• 37  Pai CH, Chiang BY, Ko TP et al. Dual binding sites for translocation catalysis by Escherichia coli glutathionylspermidine synthetase. EMBO J.25(24),5970–5982 (2006).Crossref, Medline, CAS, Google Scholar
• 38  Murzin AG. Structural classification of proteins: new superfamilies. Curr. Opin. Struct. Biol.6(3),386–394 (1996).Crossref, Medline, CAS, Google Scholar
• 39  Polekhina G, Board PG, Gali RR, Rossjohn J, Parker MW. Molecular basis of glutathione synthetase deficiency and a rare gene permutation event. EMBO J.18(12),3204–3213 (1999).Crossref, Medline, CAS, Google Scholar
• 40  Koch O, Cappel D, Nocker M et al.Molecular dynamics reveal binding mode of glutathionylspermidine by trypanothione synthetase. PLoS ONE8(2),e56788 (2013).Crossref, Medline, CAS, Google Scholar
• 41  Daunes S, D‘Silva C, Kendrick H, Yardley V, Croft SL. QSAR study on the contribution of log P and E(s) to the in vitro antiprotozoal activity of glutathione derivatives. J. Med. Chem.44,2976–2983 (2001).Crossref, Medline, CAS, Google Scholar
• 42  Kunick C, Lauenroth K, Leost M, Meijer L, Lemcke T. 1-azakenpaullone is a selectiveinhibitor of glycogen synthase kinase-3 beta. Bioorg. Med. Chem. Lett.14,413–416 (2004).Crossref, Medline, CAS, Google Scholar
• 43  Oza SL, Chen S, Wyllie S, Coward JK, Fairlamb AH. ATP-dependent ligases in trypanothione biosynthesis – kinetics of catalysis and inhibition by phosphinic acid pseudopeptides. FEBS J.275(21),5408–5421 (2008).Crossref, Medline, CAS, Google Scholar
• 44  Torrie LS, Wyllie S, Spinks D et al. Chemical validation of trypanothione synthetase, a potential drug target for human trypanosomiasis. J. Biol. Chem.284,36137–36145 (2009).Crossref, Medline, CAS, Google Scholar
• 45  Spinks D, Torrie LS, Thompson S et al. Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors. ChemMedChem7(1),95–106 (2012).Crossref, Medline, CAS, Google Scholar
• 46  Saudagar P, Dubey VK. Cloning, expression, characterization and inhibition studies on trypanothione synthetase, a drug target enzyme, from Leishmania donovani. Biol. Chem.392,1113–1122 (2011).Crossref, Medline, Google Scholar
• 47  Baiocco P, Franceschini S, Ilari A, Colotti G. Trypanothione reductase from Leishmania infantum: cloning, expression, purification, crystallization and preliminary x-ray data analysis. Protein Pept. Lett.16(2),196–200 (2009).Crossref, Medline, CAS, Google Scholar
• 48  Baiocco P, Colotti G, Franceschini S, Ilari A. Molecular basis of antimony treatment in leishmaniasis. J. Med. Chem.52(8),2603–2612 (2009).▪▪ The complex of trypanothione reductase with Sb(III) and NADPH shows the mechanism of action of antimonial drugs against leishmaniasis.Crossref, Medline, CAS, Google Scholar
• 49  Reynolds C, Damerell D, Jones S. ProtorP: a protein–protein interaction analysis server. Bioinformatics25(3),413–414 (2009).Crossref, Medline, CAS, Google Scholar
• 50  Karplus PA, Schulz GE. Substrate binding and catalysis by glutathione reductase as derived from refined enzyme: substrate crystal structures at 2 Å resolution. J. Mol. Biol.210(1),163–180 (1989).▪▪ The crystal structure of glutathione reductase shows the molecular basis of thiol reduction (see also [51]).Crossref, Medline, CAS, Google Scholar
• 51  Krauth-Siegel RL, Arscott LD, Schonleben-Janas A, Schirmer RH, Williams CH Jr. Role of active site tyrosine residues in catalysis by human glutathione reductase. Biochemistry37(40),13968–13977 (1998).Crossref, Medline, CAS, Google Scholar
• 52  Berkholz DS, Faber HR, Savvides SN, Karplus PA. Catalytic cycle of human glutathione reductase near 1 Å resolution. J. Mol. Biol.382(2),371–384 (2008).Crossref, Medline, CAS, Google Scholar
• 53  O‘Sullivan MC. The battle against trypanosomiasis and leishmaniasis: metal based and natural product inhibitors of trypanothione reductase. Curr. Med. Chem. Anti-Infect. Agents4(4),355–378 (2005).Crossref, Google Scholar
• 54  Lowe G, Droz AS, Vilaivan T et al. Cytotoxicity of (2,2´:6´,2´´-terpyridine)platinum(II) complexes to Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei. J. Med. Chem.42(6),999–1006 (1999).Crossref, Medline, CAS, Google Scholar
• 55  Bonse S, Richards JM, Ross SA, Lowe G, Krauth-Siegel RL. (2,2´:6´,2´´-Terpyridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase. J. Med. Chem.43(25),4812–4821 (2000).Crossref, Medline, CAS, Google Scholar
• 56  Navarro M, Hernandez C, Colmenares I et al. Synthesis and characterization of [Au(dppz)2]Cl3. DNA interaction studies and biological activity against Leishmania (L) mexicana. J. Inorg. Biochem.101(1),111–116 (2007).Crossref, Medline, CAS, Google Scholar
• 57  Vieites M, Smircich P, Guggeri L et al. Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action. J. Inorg. Biochem.103(10),1300–1306 (2009).Crossref, Medline, CAS, Google Scholar
• 58  Ilari A, Baiocco P, Messori L et al. A gold-containing drug against parasitic polyamine metabolism: the x-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids42(2–3),803–811 (2012).Crossref, Medline, CAS, Google Scholar
• 59  Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology16(3),112–125 (2008).Crossref, Medline, CAS, Google Scholar
• 60  Liau SY, Read DC, Pugh WJ, Furr JR, Russell AD. Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ions. Lett. Appl. Microbiol.25(4),279–283 (1997).Crossref, Medline, CAS, Google Scholar
• 61  Baiocco P. Ilari A, Ceci P et al. Inhibitory effect of silver nanoparticles on trypanothione reductase activity and Leishmania infantum proliferation. ACS Med. Chem. Lett.2,230–233 (2011).Crossref, Medline, CAS, Google Scholar
• 62  Pujals G, Sune-Negre JM, Perez P et al.In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum. Parasitol. Res.102(6),1243–1247 (2008).Crossref, Medline, CAS, Google Scholar
• 63  Jacoby EM, Schlichting I, Lantwin CB, Kabsch W, Krauth-Siegel RL. Crystal structure of the Trypanosoma cruzi trypanothione reductase mepacrine complex. Proteins24(1),73–80 (1996).Crossref, Medline, CAS, Google Scholar
• 64  Saravanamuthu A, Vickers TJ, Bond CS, Peterson MR, Hunter WN, Fairlamb AH. Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design. J. Biol. Chem.279(28),29493–29500 (2004).Crossref, Medline, CAS, Google Scholar
• 65  Garforth J, Yin H, McKie JH, Douglas KT, Fairlamb AH. Rational design of selective ligands for trypanothione reductase from Trypanosoma cruzi. Structural effects on the inhibition by dibenzazepines based on imipramine. J. Enzyme Inhib.12(3),161–173 (1997).Crossref, Medline, CAS, Google Scholar
• 66  Bonse S, Santelli-Rouvier C, Barbe J, Krauth-Siege, RL. Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure–activity relationships. J. Med. Chem.42(26),5448–5454 (1999).Crossref, Medline, CAS, Google Scholar
• 67  Salmon-Chemin L, Buisine E, Yardley V et al. 2- and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J. Med. Chem.44(4),548–565 (2001).Crossref, Medline, CAS, Google Scholar
• 68  McKie JH, Garforth J, Jaouhari R et al. Specific peptide inhibitors of trypanothione reductase with backbone structures unrelated to that of substrate: potential rational drug design lead frameworks. Amino Acids20(2),145–153 (2001).Crossref, Medline, CAS, Google Scholar
• 69  Stump B, Eberle C, Kaiser M et al. Diaryl sulfide-based inhibitors of trypanothione reductase: inhibition potency, revised binding mode and antiprotozoal activities. Org. Biomol. Chem.6(21),3935–3947 (2008).Crossref, Medline, CAS, Google Scholar
• 70  Patterson S, Alphey MS, Jones DC et al. Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: discovery, synthesis, and characterization of their binding mode by protein crystallography. J. Med. Chem.54(19),6514–6530 (2011).Crossref, Medline, CAS, Google Scholar
• 71  Wood ZA, Poole LB, Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science300(5619),650–653 (2003).Crossref, Medline, CAS, Google Scholar
• 72  Olin-Sandoval V, Moreno-Sanchez R, Saavedra E. Targeting trypanothione metabolism in trypanosomatid human parasites. Curr. Drug Targets11(12),1614–1630 (2010).Crossref, Medline, CAS, Google Scholar
• 73  Flohe L. The trypanothione system and the opportunities it offers to create drugs for the neglected kinetoplast diseases. Biotechnol. Adv.30(1),294–301 (2012).Crossref, Medline, CAS, Google Scholar
• 74  Alphey MS, Bond CS, Tetaud E, Fairlamb AH, Hunter WN. The structure of reduced tryparedoxin peroxidase reveals a decamer and insight into reactivity of 2Cys-peroxiredoxins. J. Mol. Biol.300(4),903–916 (2000).Crossref, Medline, CAS, Google Scholar
• 75  Alphey MS, Konig J, Fairlamb AH. Structural and mechanistic insights into type II trypanosomatid tryparedoxin-dependent peroxidases. Biochem J.414(3),375–381 (2008).Crossref, Medline, CAS, Google Scholar
• 76  Cao Z, Tavender TJ, Roszak AW, Cogdell RJ, Bulleid NJ. Crystal structure of reduced and of oxidized peroxiredoxin IV enzyme reveals a stable oxidized decamer and a non-disulfide-bonded intermediate in the catalytic cycle. J. Biol. Chem.286(49),42257–42266 (2011).Crossref, Medline, CAS, Google Scholar
• 77  Fiorillo A, Colotti G, Boffi A, Baiocco P, Ilari A. The crystal structures of the tryparedoxin-tryparedoxin peroxidase couple unveil the structural determinants of Leishmania detoxification pathway. PLoS Negl. Trop. Dis.6(8),e1781 (2012).Crossref, Medline, CAS, Google Scholar
• 78  Wang X, Wang L, Sun F, Wang CC. Structural insights into the peroxidase activity and inactivation of human peroxiredoxin 4. Biochem. J.441(1),113–118 (2012).Crossref, Medline, CAS, Google Scholar
• 79  Budde H, Flohe L, Hecht HJ et al. Kinetics and redox-sensitive oligomerisation reveal negative subunit cooperativity in tryparedoxin peroxidase of Trypanosoma brucei brucei. Biol. Chem.384(4),619–633 (2003).Crossref, Medline, CAS, Google Scholar
• 80  Comini MA, Flohé L.Trypanothione-based redox metabolism of trypanosomatids. In: Trypanosomatid Diseases. Jäger T, Koch O, Flohé L (Eds). Wiley-Blackwell, Weinheim, Germany, 167–199 (2013).Google Scholar
• 81  Beig M, Oellien F, Krauth-Siegel RL, Selzer PM. Screening approaches towards trypanothione reductase. In: Trypanosomatid Diseases. Jäger T, Koch O, Flohé L (Eds). Wiley-Blackwell, Weinheim, Germany, 385–404 (2013).Google Scholar
• 82  Lee B, Bauer H, Melchers J et al. Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate. J. Med. Chem.48,7400–7410 (2005).Crossref, Medline, CAS, Google Scholar